Background Checkpoint kinase 2 （CHK2） is a DNA damage-activated protein kinase which is involved in cell cycle checkpoint control, CHK2 gene could be a candidate gene for colorectal cancer susceptibility, But there ...Background Checkpoint kinase 2 （CHK2） is a DNA damage-activated protein kinase which is involved in cell cycle checkpoint control, CHK2 gene could be a candidate gene for colorectal cancer susceptibility, But there are few systematic reports on mutation of CHK2 in colorectal cancer. Methods The mutations of all 14 exons of CHK2 in 56 colorectal cancer cell lines were screened systematically, using denaturing high-performance liquid chromatography （DHPLC） to screen the mismatches of the CHK2 exons amplified products, and then the suspected mutant cell lines were scanned by nucleotide sequence analysis. Results VACO400 in CHK2 exon la was suspected to have mutation by DHPLC and confirmed by sequence, but this was nonsense mutation. C106, CX-1, HT-29, SK01, SW480, SW620 and VACO400 in CHK2 exon lb were confirmed to have the same nonsense mutation in 11609 A〉G. DLD-1 and HCT-15 in CHK2 exon 2 were confirmed to have missense mutation R145W, which was heterozygous C〉T missense mutation at nucleotide 433, leading to an Arg〉Trp substitution within the FHA domain. Conclusions The CHK2 mutation in colorectal cancer is a low frequency event, There are just 10 cell lines to have sequence variations in all the 14 exons in 56 colorectal cancer cell lines and only DLD-1/HCT-15 had heterozygous missense mutation. These findings may give useful information of susceptibility of colorectal cancer as single nucleotide polvmorphvsim.展开更多
目的探讨趋化因子受体CXCR3B(CXC型趋化因子受体3变体B)在结肠癌组织中的表达及对结肠癌LOVO细胞株迁移能力的影响。方法常规收取结直肠癌及癌旁组织标本,用免疫组织化学(IHC)染色方法检测CXCR3B的表达;实时荧光定量PCR(q RT-PCR)检测...目的探讨趋化因子受体CXCR3B(CXC型趋化因子受体3变体B)在结肠癌组织中的表达及对结肠癌LOVO细胞株迁移能力的影响。方法常规收取结直肠癌及癌旁组织标本,用免疫组织化学(IHC)染色方法检测CXCR3B的表达;实时荧光定量PCR(q RT-PCR)检测正常肠上皮细胞株NCM460及结肠癌细胞株LOVO中的CXCR3B m RNA表达,过表达CXCR3B-RFP慢病毒感染LOVO细胞株,划痕实验及transwell实验检测LOVO细胞株的迁移变化。结果免疫组织化学结果显示在结直肠癌旁组织中CXCR3B的表达显著高于癌组织(P<0.001);NCM460细胞中CXCR3B m RNA表达高于LOVO细胞表达(P<0.01)。划痕实验及transwell迁移实验显示过表达CXCR3B组(LOVO-CXCR3B)细胞迁移较阴性对照组(LOVO-NC)低(P<0.01)。结论人结直肠癌组织中CXCR3B低表达,过表达CXCR3B可抑制结肠癌细胞株LOVO的迁移。展开更多
基金China-Korea Young Scientist Exchange Program(2004), Biomedical Research Institute of Kyungpook National University Hospital.
文摘Background Checkpoint kinase 2 （CHK2） is a DNA damage-activated protein kinase which is involved in cell cycle checkpoint control, CHK2 gene could be a candidate gene for colorectal cancer susceptibility, But there are few systematic reports on mutation of CHK2 in colorectal cancer. Methods The mutations of all 14 exons of CHK2 in 56 colorectal cancer cell lines were screened systematically, using denaturing high-performance liquid chromatography （DHPLC） to screen the mismatches of the CHK2 exons amplified products, and then the suspected mutant cell lines were scanned by nucleotide sequence analysis. Results VACO400 in CHK2 exon la was suspected to have mutation by DHPLC and confirmed by sequence, but this was nonsense mutation. C106, CX-1, HT-29, SK01, SW480, SW620 and VACO400 in CHK2 exon lb were confirmed to have the same nonsense mutation in 11609 A〉G. DLD-1 and HCT-15 in CHK2 exon 2 were confirmed to have missense mutation R145W, which was heterozygous C〉T missense mutation at nucleotide 433, leading to an Arg〉Trp substitution within the FHA domain. Conclusions The CHK2 mutation in colorectal cancer is a low frequency event, There are just 10 cell lines to have sequence variations in all the 14 exons in 56 colorectal cancer cell lines and only DLD-1/HCT-15 had heterozygous missense mutation. These findings may give useful information of susceptibility of colorectal cancer as single nucleotide polvmorphvsim.
文摘目的探讨趋化因子受体CXCR3B(CXC型趋化因子受体3变体B)在结肠癌组织中的表达及对结肠癌LOVO细胞株迁移能力的影响。方法常规收取结直肠癌及癌旁组织标本,用免疫组织化学(IHC)染色方法检测CXCR3B的表达;实时荧光定量PCR(q RT-PCR)检测正常肠上皮细胞株NCM460及结肠癌细胞株LOVO中的CXCR3B m RNA表达,过表达CXCR3B-RFP慢病毒感染LOVO细胞株,划痕实验及transwell实验检测LOVO细胞株的迁移变化。结果免疫组织化学结果显示在结直肠癌旁组织中CXCR3B的表达显著高于癌组织(P<0.001);NCM460细胞中CXCR3B m RNA表达高于LOVO细胞表达(P<0.01)。划痕实验及transwell迁移实验显示过表达CXCR3B组(LOVO-CXCR3B)细胞迁移较阴性对照组(LOVO-NC)低(P<0.01)。结论人结直肠癌组织中CXCR3B低表达,过表达CXCR3B可抑制结肠癌细胞株LOVO的迁移。
